Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
Is the rebound fading? Goldman Sachs: Hedge funds are selling stocks at the fastest pace in more than two years.
In August, 'smart money' is selling global equities at the fastest pace since March 2022, with the most net selling in North America. Hedge funds are skeptical of the sustainability of the stock market rebound, and geopolitical concerns continue to be worrying. The 'fly' of the economic situation may soon hit the glass windshield.
Should You Be Excited About AbbVie Inc.'s (NYSE:ABBV) 78% Return On Equity?
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Express News | Abbvie : Piper Sandler Raises Target Price to $209 From $196
In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge
The 20 Most Popular Mutual Fund Increases During 2Q - Goldman Sachs
Unpacking the Latest Options Trading Trends in AbbVie
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
ABBV.US's potential blockbuster bispecific antibody therapy has once again been approved by the European Union.
On August 20th, AbbVie (ABBV.US) and genmab (GMAB.US) jointly announced that the European Commission has approved Tepkinly (epcoritamab) for expanded indications for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adult patients.
EC Approves AbbVie's TEPKINLY for Follicular Lymphoma
AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization
NYSE New 52-Week Highs And Lows